ANNOUNCING THE FORMATION OF THE PROJECT'S ADVISORY BOARD
January 13, 2009 - Laguna Woods, CA
The Project Charity – Children’s Rare Disease Network announces the formation of it’s Advisory Board, joined by an international group of experts in both science & business. “The Project is honored to have these men and women join our board, all bringing unique expertise and talent in critical areas, important to the growth and build out of The Project and its Children’s Rare Disease Network,” stated The Project’s founder and CEO, Mrs. Nicole Boice.
Segolene Ayme, MD, PhD. joins the board as a Medical geneticist and epidemiologist, the Director of Research INSERM, founder and director of Orphanet since 1997, Expert to the European Commission since 1996, Leader of the Rare Disease Task Force of DG Public Health since 2004, President of the French Society of Human Genetics since 2004, Member of the ICD revision steering group for WHO since 2007 and Chair WHO Topical Advisory Group for Rare Diseases since 2007. She currently resides in Paris, France
Mrs. Beth Ann Baber joins the board as the Co-founder and Executive VP and COO The Nicholas Conor Institute for Pediatric Cancer Research. Dr. Baber received her Ph.D. in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute and carried out her postdoctoral studies at The Salk Institute for Biological Studies. She has over 14 years of academic experience in molecular biology, neurobiology and physiology, cell and developmental biology, cancer biology, and signal transduction. In 2007, Dr. Baber co-founded The Nicholas Conor Institute for Pediatric Cancer Research after her son, Nicholas Conor Boddy, was diagnosed with neuroblastoma.
Dr. John Douglas joins the board as a pediatrician by training. Affiliated with Georgetown University School of Medicine, Loma Linda University Medical Center and UCLA where he studied Microbiology and Molecular Genetics. During medical school he worked with the Division of Genetics at the UCLA Medical Center to evaluate the efficacy of genetic studies in determining the etiology of non-specific genetic disorders.
Mr. Brad Margus joins the board as CEO of Envoy Therapeutics, co-founder and Executive Vice Chairman of Perlegen Sciences. He has served on the Advisory Council to the National Institute of Neurological Disorders and Stroke, on the Secretary of Health and Human Services Advisory Committee on Genetics, Health and Society, and on the Board of the Genetic Alliance. He continues to serve as Chairman and volunteer president of the A-T Children’s Project; on the Board of Children’s Neurobiological Solutions, an organization aimed at applying brain repair and regeneration to pediatric neurological disorders; and on the Stem Cell Research Oversight Committee at the Stanford University School of Medicine.
In addition to our Advisory Board, The Project is working to engage a handful of key business men and women to join our Board of Directors that will help drive our initial success and funding needs. Together, the Advisory Board, The Board of Directors and executive staff will be working to accomplish much this upcoming 2009.
Return to the news page.
